Life forward - Boehringer Ingelheim unveils its evolved company brand
Ingelheim, Germany, 30/10/2023 | Boehringer Ingelheim, a leading research-driven biopharmaceutical company, on Monday presented a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners
Read more about INSPIRED, aimed at expanding a hospital-to-home program to better support people living with chronic obstructive pulmonary disease (COPD).
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
Using AI to power patient-centric guideline optimization: discover the collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health.
Improving primary care in Alberta’s Indigenous Populations. Read more about ABIC, an example of how delivering innovative solutions can improve health equity.
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.